Printer Friendly

PFIZER FILES PATENT INFRINGEMENT SUIT AGAINST SCHUYLER LABS

 PFIZER FILES PATENT INFRINGEMENT SUIT AGAINST SCHUYLER LABS
 NEW YORK, June 2 /PRNewswire/ -- Pfizer Inc announced today that it has filed suit against an Illinois supplier of animal health products for infringement of the patent covering Liquamycin(A) LA-200(A), Pfizer's unique long-acting injectable form of oxytetracycline, an antibiotic used in animals.
 Named as the defendant in the Pfizer complaint was Schuyler Laboratories, Inc., a Nevada corporation headquartered in Rushville, Ill. The suit was filed in the United States District Court for the Northern District of Illinois.
 The complaint seeks an order barring the defendant from making, using or selling oxytetracycline compositions covered by Pfizer's patent, and from inducing others to infringe or contributing to the infringement by others of that patent. It also asks that Pfizer be awarded damages adequate to compensate it for the defendant's infringement, along with attorney's fees and costs.
 A Pfizer spokesperson emphasized that Pfizer makes substantial investments each year in the search for new and better animal health products, and that the firm will vigorously enforce the patents protecting these products.
 Pfizer Inc is a research-based, diversified health care company with global operations. The company reported sales of approximately $6.95 billion for 1991.
 (A) Liquamycin and LA-200 are registered trademarks of Pfizer Inc.
 -0- 6/2/92
 /CONTACT: Jan Westmoreand, 212-573-7203, or A.A. Biesada, 212-573-2055, both of Pfizer/
 (PFE) CO: Pfizer Inc.; Schuyler Laboratories, Inc. ST: New York, Illinois IN: MTC SU:


SM-LR -- NY074 -- 6406 06/02/92 17:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1992
Words:249
Previous Article:APA OPTICS REPORTS YEAR-END RESULTS
Next Article:DEL WEBB SUCCESSFULLY COMPLETES CONVERSION OF DEBT TO EQUITY
Topics:


Related Articles
VALLEYLAB FILES DECLARATORY JUDGMENT SUIT AGAINST BIRTCHER MEDICAL SYSTEMS
Embrex Announces Developments in Patent Litigation
SIBIA Neurosciences, Inc. Announces Filing of Counterclaim Against Pfizer Inc. for Patent Infringement.
Generics disputes continue. (Policy & Practice).
Pfizer Prevails in Accupril Patent Suit.
Pfizer Files Suit Against Internet Site for Selling Copy of Lipitor.
Pfizer Prevails in Accupril Patent Suit.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters